Maze Therapeutics, Inc.
MAZE
$14.29
$0.987.36%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -318.68% | 147.93% | 152.02% | -- | -- |
| Total Depreciation and Amortization | -25.32% | -23.93% | -19.37% | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -5.69% | -12.86% | 38.79% | -- | -- |
| Change in Net Operating Assets | -578.39% | 9.98% | 75.89% | -- | -- |
| Cash from Operations | -229.91% | 180.17% | 187.48% | -- | -- |
| Capital Expenditure | -197.87% | -126.60% | -160.09% | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -197.87% | -126.60% | -160.09% | -- | -- |
| Total Debt Issued | -100.00% | -99.36% | 51.30% | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 27,654.09% | 26,645.78% | 250.72% | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -1,785.87% | -- | -- | -- | -- |
| Cash from Financing | 379.10% | 378.68% | 466.66% | -- | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -26.33% | 664.84% | 336.52% | -- | -- |